Brief: AB Science Authorised To File New Drug Submission For masitinib

AB Science SA

21/02/2022 17:01

Feb 21 (Reuters) - AB SCIENCE SA  ABS.PA :
    * AB SCIENCE ANNOUNCES THAT HEALTH CANADA HAS GRANTED
AUTHORIZATION TO FILE A NEW DRUG SUBMISSION FOR MASITINIB IN THE
TREATMENT OF ALS UNDER THE NOTICE OF COMPLIANCE WITH CONDITIONS
(NOC/C) POLICY
    * AN ASSESSMENT NAMED ADVANCE CONSIDERATION, PERFORMED BY A
HEALTH
CANADA ADJUDICATING COMMITTEE, IS NECESSARY BEFORE BEING GRANTED
AUTHORIZATION TO FILE UNDER NOC/C POLICY
    * ADJUDICATING COMMITTEE HAS CONCLUDED THAT REQUEST DOES
FULFILL
CRITERIA FOR FILING AND ADVANCE CONSIDERATION UNDER NOC/C POLICY
    * IF GRANTED, AN NOC/C IS AUTHORIZATION TO MARKET A DRUG
WITH
CONDITIONS
    * SUCH CONDITIONS WILL BE DISCUSSED WITH HEALTH CANADA
DURING
PROCEDURE

Source text for Eikon:  ID:nGNE8GfzYv 
Further company coverage:  ABS.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 772 09 20;))